全文获取类型
收费全文 | 923篇 |
免费 | 27篇 |
国内免费 | 28篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 15篇 |
基础医学 | 62篇 |
口腔科学 | 8篇 |
临床医学 | 69篇 |
内科学 | 490篇 |
皮肤病学 | 3篇 |
神经病学 | 18篇 |
特种医学 | 88篇 |
外科学 | 55篇 |
综合类 | 13篇 |
预防医学 | 32篇 |
眼科学 | 19篇 |
药学 | 27篇 |
肿瘤学 | 78篇 |
出版年
2021年 | 5篇 |
2020年 | 4篇 |
2019年 | 6篇 |
2018年 | 9篇 |
2016年 | 8篇 |
2015年 | 13篇 |
2014年 | 14篇 |
2013年 | 17篇 |
2012年 | 23篇 |
2011年 | 16篇 |
2010年 | 27篇 |
2009年 | 20篇 |
2008年 | 27篇 |
2007年 | 25篇 |
2006年 | 44篇 |
2005年 | 31篇 |
2004年 | 27篇 |
2003年 | 20篇 |
2002年 | 36篇 |
2001年 | 33篇 |
2000年 | 36篇 |
1999年 | 40篇 |
1998年 | 20篇 |
1997年 | 16篇 |
1996年 | 31篇 |
1995年 | 24篇 |
1994年 | 27篇 |
1993年 | 17篇 |
1992年 | 25篇 |
1991年 | 33篇 |
1990年 | 27篇 |
1989年 | 32篇 |
1988年 | 32篇 |
1987年 | 34篇 |
1986年 | 21篇 |
1985年 | 28篇 |
1984年 | 16篇 |
1983年 | 14篇 |
1982年 | 11篇 |
1981年 | 14篇 |
1980年 | 8篇 |
1979年 | 10篇 |
1978年 | 4篇 |
1977年 | 9篇 |
1976年 | 4篇 |
1975年 | 3篇 |
1973年 | 3篇 |
1972年 | 10篇 |
1970年 | 3篇 |
1966年 | 4篇 |
排序方式: 共有978条查询结果,搜索用时 15 毫秒
1.
2.
3.
Staging and prognosis in chronic myelogenous leukemia 总被引:8,自引:0,他引:8
4.
33 patients with advanced refractory multiple myeloma received a combination of vincristine, cyclophosphamide, carmustine, melphalan and steroids (M-2 protocol). 20 of them had failed prior chemotherapy with alkylating agents and the remaining 13 patients had relapsed after a response to these drugs. An objective tumour cell mass reduction (greater than or equal to 50%) was achieved in 17% of the patients (6% of previously nonresponders and 33% of previously relapsing), while 9 additional patients improved (30-50% tumour reduction), for an overall response rate of 47% (39% for previously nonresponders and 58% for previously relapsing). The median duration of response was 7 months. Thrombocytopenia was the most common toxicity encountered in the study (39% of cases). Our findings indicate that M-2 protocol is an effective salvage treatment for patients who relapse from previous chemotherapy with alkylating agents. In contrast, results in patients who are primarily resistant to these drugs justify the search for different treatment programmes which can produce greater degrees of tumour reduction. 相似文献
5.
6.
7.
G. Martinelli P. Farabegoli M. Buzzi G. Panzica A. Zaccaria G. Bandini E. Calori N. Testoni G. Rosti R. Conte C. Remiddi M. Salvucci A. De Vivo S. Tura 《International journal of immunogenetics》1996,23(1):55-65
The degree of matching of HLA genes between the selected donor and recipient is an important aspect of the selection of unrelated donors for allogeneic bone marrow transplantation (UBMT). The most sensitive methods currently used are serological typing of HLA class I genes, mixed lymphocyte culture (MLC), IEF and molecular genotyping of HLA class II genes by direct sequencing of PCR products. Serological typing of class I antigenes (A, B and C) fails to detect minor differences demonstrated by direct sequencing of DNA polymorphic regions. Molecular genotyping of HLA class I genes by DNA analysis is costly and work-intensive. To improve compatibility between donor and recipient, we have set up a new rapid and non-radioisotopic application of the ‘fingerprinting PCR’ technique for the analysis of the polymorphic second exon of the HLA class I A, B and C genes. This technique is based on the formation of specific patterns (PCR fingerprints) of homoduplexes and heterodu-plexes between heterologous amplified DNA sequences. After an electrophoretic run on non-denaturing polyacrylamide gel, different HLA class I types give allele-specific banding patterns. HLA class I matching is performed, after the gel has been soaked in ethidium bromide or silver-stained, by visual comparison of patients’ fingerprints with those of donors. Identity can be confirmed by mixing donor and recipient DNAs in an amplification cross-match. To assess the technique, 10 normal samples, 22 related allogeneic bone marrow transplanted pairs and 10 unrelated HLA-A and HLA-B serologically matched patient-donor pairs were analysed for HLA class I polymorphic regions. In all the related pairs and in 1/10 unrelated pairs, matched donor-recipient patterns were identified. This new application of PCR fingerprinting may confirm the HLA class I serological selection of unrelated marrow donors. 相似文献
8.
Mario Arpinati Gabriella Chirumbolo Benedetta Urbini Francesca Bonifazi Giuseppe Bandini Yogen Saunthararajah Alessandra Zagnoli Marta Stanzani Sadia Falcioni Giulia Perrone Sante Tura Michele Baccarani Damiano Rondelli 《Biology of blood and marrow transplantation》2004,10(2):106-115
Human dendritic cells (DC) comprise 2 subsets-plasmacytoid CD123(+) and myeloid CD11c(+) DC-that may have distinct roles in the regulation of immunity after allogeneic hematopoietic stem cell transplantation. In this study, we analyzed the kinetics of CD123(+) DC and CD11c(+) DC reconstitution in 31 patients who underwent transplantation with allogeneic granulocyte colony-stimulating factor-mobilized peripheral blood (PB) stem cells from HLA-identical sibling donors after myeloablative conditioning. Lineage marker-negative HLA-DR(+) CD11c(+) CD11c(+) DC and lineage marker-negative HLA-DR(+) CD123(+) CD123(+) DC, as well as monocytes and lymphoid subsets, were enumerated in donor grafts and in the PB of patients at various time points after transplantation. Reconstitution of both CD11c(+) DC and CD123(+) DC to normal levels occurred within 6 to 12 months and was not affected by the diagnosis, preparatory regimen, or graft composition. However, PB CD11c(+) DC and CD123(+) DC counts were significantly reduced in patients with acute GVHD grade II to IV (at 1 and 3 months) and grade I (at 1 month). Patients with chronic GVHD instead showed reduced CD123(+) DC counts only 6 months after transplantation. Moreover, treatment with steroids (>0.1 mg/kg) was significantly associated with reduced PB CD11c(+) DC and CD123(+) DC counts at all time points after transplantation. In multivariate analysis, only acute GVHD affected DC reconstitution early after transplantation. These results will prompt new studies addressing whether DC reconstitution correlates with immunity against infectious agents or with graft-versus-tumor reactions after PB stem cell allotransplantation. 相似文献
9.
10.